{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:20:01Z","timestamp":1778548801206,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["B2017\/BMD-3686 CIFRA2-CM"],"award-info":[{"award-number":["B2017\/BMD-3686 CIFRA2-CM"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["FIS CP14\/00133"],"award-info":[{"award-number":["FIS CP14\/00133"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["PI16\/02057"],"award-info":[{"award-number":["PI16\/02057"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["PI18\/01366"],"award-info":[{"award-number":["PI18\/01366"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["DTS18\/00032"],"award-info":[{"award-number":["DTS18\/00032"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["ERA-PerMed-JTC2018"],"award-info":[{"award-number":["ERA-PerMed-JTC2018"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["ATTACK AC18\/00064"],"award-info":[{"award-number":["ATTACK AC18\/00064"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["PERSTIGAN AC18\/00071"],"award-info":[{"award-number":["PERSTIGAN AC18\/00071"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda","award":["REDinREN RD016\/0009"],"award-info":[{"award-number":["REDinREN RD016\/0009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this issue of Clinical Kidney Journal, Plasse et al. report on the use of high-dose aliskiren as an adjunct therapy in a patient treated with eculizumab for haemolytic uraemic syndrome (HUS). This follows the recent description of the complement factor 3 (C3) activating activity of the enzyme renin and the successful therapeutic use of the direct renin inhibitor aliskiren in three cases of C3 glomerulopathy\/dense deposit disease. We discuss the potential clinical and pathophysiological implications of these reports on nephropathies linked to complement, from HUS to C3 glomerulopathy to immunoglobulin A nephropathy as well as the concept of dual complement inhibition for kidney disease.<\/jats:p>","DOI":"10.1093\/ckj\/sfz142","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T07:38:04Z","timestamp":1568792284000},"page":"35-38","source":"Crossref","is-referenced-by-count":8,"title":["Aliskiren and the dual complement inhibition concept"],"prefix":"10.1093","volume":"13","author":[{"given":"Maria Vanessa","family":"Perez-Gomez","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain"},{"name":"Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain"},{"name":"Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"2020021705494198700_sfz142-B1","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfz146","article-title":"Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome","volume":"13","author":"Plasse","year":"2020","journal-title":"Clin Kidney J"},{"key":"2020021705494198700_sfz142-B2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","article-title":"Aliskiren inhibits renin-mediated complement activation","volume":"94","author":"B\u00e9k\u00e1ssy","year":"2018","journal-title":"Kidney Int"},{"key":"2020021705494198700_sfz142-B3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1470320313497328","article-title":"Review of direct renin inhibition by aliskiren","volume":"14","author":"Friedrich","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2020021705494198700_sfz142-B4"},{"key":"2020021705494198700_sfz142-B5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2042098615589905","article-title":"Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function","volume":"6","author":"Esteras","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"2020021705494198700_sfz142-B6"},{"key":"2020021705494198700_sfz142-B7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev-physiol-012110-142238","article-title":"Renin release: sites, mechanisms, and control","volume":"73","author":"Kurtz","year":"2011","journal-title":"Annu Rev Physiol"},{"key":"2020021705494198700_sfz142-B8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrneph.2017.186","article-title":"Renin cells in homeostasis, regeneration and immune defence mechanisms","volume":"14","author":"Gomez","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2020021705494198700_sfz142-B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2369-13-21","article-title":"Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?","volume":"13","author":"Fernandez-Fernandez","year":"2012","journal-title":"BMC Nephrol"},{"key":"2020021705494198700_sfz142-B10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.kint.2018.05.025","article-title":"A novel role of renin inhibitor in the complement cascade","volume":"94","author":"Nakano","year":"2018","journal-title":"Kidney Int"},{"key":"2020021705494198700_sfz142-B11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol Immunol"},{"key":"2020021705494198700_sfz142-B12","first-page":"139","article-title":"Kidney Disease: Improving Global Outcomes Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2020021705494198700_sfz142-B13","doi-asserted-by":"crossref","first-page":"e62736","DOI":"10.1371\/journal.pone.0062736","article-title":"The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy \u2013 a randomized cross-over study","volume":"8","author":"Szeto","year":"2013","journal-title":"PLoS One"},{"key":"2020021705494198700_sfz142-B14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfr349","article-title":"Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study","volume":"27","author":"Tang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705494198700_sfz142-B15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1574887113666180726103648","article-title":"Successful use of aliskiren in a case of IgA\u2013 mesangial glomerulonephritis unresponsive to conventional therapies","volume":"14","author":"Simeoni","year":"2019","journal-title":"Rev Recent Clin Trials"},{"key":"2020021705494198700_sfz142-B16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.RES.0000182677.89816.38","article-title":"Complement activation in angiotensin II-induced organ damage","volume":"97","author":"Shagdarsuren","year":"2005","journal-title":"Circ Res"},{"key":"2020021705494198700_sfz142-B17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ckj\/sfv065","article-title":"Timing of eculizumab therapy for C3 glomerulonephritis","volume":"8","author":"Rodriguez-Osorio","year":"2015","journal-title":"Clin Kidney J"},{"key":"2020021705494198700_sfz142-B18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200746080-00003","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment","volume":"46","author":"Vaidyanathan","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2020021705494198700_sfz142-B19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/HJH.0b013e32835e226b","article-title":"Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin","volume":"31","author":"Lange","year":"2013","journal-title":"J Hypertens"},{"key":"2020021705494198700_sfz142-B20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1096\/fj.05-4747com","article-title":"Local extravascular pool of C3 is a determinant of postischemic acute renal failure","volume":"20","author":"Farrar","year":"2006","journal-title":"FASEB J"},{"key":"2020021705494198700_sfz142-B21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1096\/fj.07-8719com","article-title":"Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury","volume":"22","author":"Sheerin","year":"2008","journal-title":"FASEB J"},{"key":"2020021705494198700_sfz142-B22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1681\/ASN.2007060686","article-title":"Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury","volume":"19","author":"Abbate","year":"2008","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/1\/35\/32500156\/sfz142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/1\/35\/32500156\/sfz142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T05:51:18Z","timestamp":1581918678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/1\/35\/5603537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,23]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz142","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,10,23]]}}}